Activated protein C inhibits lipopolysaccharide-mediated acetylation and secretion of high-mobility group box 1 in endothelial cells.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
05 2019
Historique:
received: 30 01 2019
pubmed: 14 3 2019
medline: 11 7 2020
entrez: 14 3 2019
Statut: ppublish

Résumé

Essentials APC elicits cytoprotective responses in endothelial cells via EPCR-dependent cleavage of PAR1. APC inhibits LPS-mediated translocation and extracellular secretion of HMGB1 in endothelial cells. Signaling activity of APC inhibits LPS-mediated acetylation of HMGB1 by epigenetic mechanisms. APC inhibits LPS-mediated HMGB1 expression in CD31-positive endothelial cells in cremaster muscle. SUMMARY: Background Activated protein C (APC) inhibits high-mobility group box 1 (HMGB1) signaling and its lipopolysaccharide (LPS)-mediated release by endothelial protein C receptor (EPCR)-dependent activation of protease-activated receptor 1 (PAR1) in endothelial cells. Post-translational acetylation is known to modulate the subcellular localization of HMGB1, and its hyperacetylated form is translocated to the cytoplasm of innate immune cells before being secreted into the extracellular space. Objective To determine whether APC inhibits LPS-mediated HMGB1 secretion from endothelial cells by modulating its acetylation status. Methods The subcellular localization of HMGB1 in LPS-treated endothelial cells was monitored in the absence and presence of APC by western blot analysis of fractionated cell lysates and confocal immunofluorescence microscopy. Results Both western blot and immunofluorescence data indicated that APC effectively inhibits LPS-mediated translocation of HMGB1 from the nucleus to the cytoplasm by EPCR-dependent and PAR1-dependent mechanisms. When EPCR was ligated by the Gla-domain of protein C/APC, thrombin also inhibited LPS-mediated HMGB1 translocation. Further studies revealed that APC inhibits the translocation of HMGB1 from the nucleus to the cytoplasm by inhibiting LPS-mediated hyperacetylation of HMGB1 by (de)acetylating enzymes. Furthermore, the translocated HMGB1 was found to be associated with lysosome-associated membrane protein 1 in LPS-treated endothelial cells. The in vivo relevance of these findings was investigated in the mouse cremaster muscle, and this demonstrated that both wild-type APC and a signaling-selective mutant of APC inhibit LPS-mediated HMGB1 expression and translocation in CD31-positive endothelial cells. Conclusion These results suggest that APC inhibits LPS-mediated cytoplasmic translocation and secretion of HMGB1 in endothelial cells by epigenetic mechanisms.

Identifiants

pubmed: 30865333
doi: 10.1111/jth.14425
pmc: PMC6494677
mid: NIHMS1017761
pii: S1538-7836(22)05363-6
doi:

Substances chimiques

HMGB1 Protein 0
HMGB1 protein, human 0
HMGB1 protein, mouse 0
Lipopolysaccharides 0
PECAM1 protein, human 0
Pecam1 protein, mouse 0
Platelet Endothelial Cell Adhesion Molecule-1 0
Protein C 0
Receptor, PAR-1 0
TLR4 protein, human 0
Tlr4 protein, mouse 0
Toll-Like Receptor 4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

803-817

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL062565
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL101917
Pays : United States

Informations de copyright

© 2019 International Society on Thrombosis and Haemostasis.

Références

Blood. 2015 Apr 30;125(18):2845-54
pubmed: 25733582
Blood. 2012 Dec 20;120(26):5237-46
pubmed: 23149848
J Exp Med. 2000 Aug 21;192(4):565-70
pubmed: 10952726
Science. 1999 Jul 9;285(5425):248-51
pubmed: 10398600
J Immunol. 2014 Dec 15;193(12):6114-23
pubmed: 25392528
Thromb Haemost. 2009 Mar;101(3):513-20
pubmed: 19277413
Nat Rev Immunol. 2005 Apr;5(4):331-42
pubmed: 15803152
Blood. 2014 Feb 6;123(6):935-45
pubmed: 24255918
PLoS One. 2012;7(7):e41932
pubmed: 22860034
J Biol Chem. 2007 Mar 23;282(12):9251-9
pubmed: 17255099
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1868-1877
pubmed: 29930000
Blood. 2007 Dec 1;110(12):3909-16
pubmed: 17823308
Blood. 2017 Jul 13;130(2):181-191
pubmed: 28515093
Mol Med. 2015 Mar 12;20:612-24
pubmed: 25517228
Blood. 2011 Oct 6;118(14):3952-9
pubmed: 21849480
J Clin Invest. 2010 Jun;120(6):1971-80
pubmed: 20458145
Biochemistry. 2004 Mar 16;43(10):2935-40
pubmed: 15005629
FASEB J. 1995 Jul;9(10):946-55
pubmed: 7615164
Blood. 2014 Sep 4;124(10):1553-62
pubmed: 25049281
Blood. 2007 Apr 15;109(8):3161-72
pubmed: 17110453
Thromb Haemost. 2014 Nov;112(5):876-82
pubmed: 24990498
Science. 2002 Jun 7;296(5574):1880-2
pubmed: 12052963
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10212-6
pubmed: 8816778
Nat Rev Mol Cell Biol. 2002 Feb;3(2):122-31
pubmed: 11836514
Blood. 2003 Jun 15;101(12):4797-801
pubmed: 12586611
J Biol Chem. 2010 Dec 17;285(51):39888-97
pubmed: 20937823
J Exp Med. 2007 Oct 1;204(10):2439-48
pubmed: 17893198
EMBO Rep. 2002 Oct;3(10):995-1001
pubmed: 12231511
Nat Rev Genet. 2009 Jan;10(1):32-42
pubmed: 19065135
J Interferon Cytokine Res. 2004 Jun;24(6):329-33
pubmed: 15212706
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890
Sci Rep. 2015 Nov 02;5:15971
pubmed: 26522327
J Thromb Haemost. 2017 Jul;15(7):1273-1284
pubmed: 28671351
Acad Emerg Med. 2004 Aug;11(8):867-73
pubmed: 15289194
Mol Immunol. 2005 Feb;42(4):433-44
pubmed: 15607795
J Biol Chem. 2007 Jun 15;282(24):17845-54
pubmed: 17430886
Blood. 2016 Oct 6;128(14):1884-1893
pubmed: 27561318
EMBO J. 2003 Oct 15;22(20):5551-60
pubmed: 14532127

Auteurs

Xiaofeng Cai (X)

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Indranil Biswas (I)

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Sumith R Panicker (SR)

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Hemant Giri (H)

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Alireza R Rezaie (AR)

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH